After Aurinia Pharmaceuticals (AUPH) announced an agreement to acquire Kezar Life Sciences (KZR) for $6.955 in cash per share plus one non-transferable contingent value right, Jefferies said the deal valuation “makes sense” given the stage of development and trials needed to bring zetomipzomib to market. The firm maintains a Hold rating and $7 price target on Kezar shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZR:
- Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane
- Kezar Life Sciences to Be Acquired by Aurinia
- Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR
- Kezar Divests Sec61 Program to Refocus on Core Pipeline
- KZR Earnings Report this Week: Is It a Buy, Ahead of Earnings?